Recent Updates
Recently added Catalysts
PCRX Negative Sentiment Score: 20/100

PACIRA BIOSCIENCES SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Pacira BioSciences, Inc. - PCRX

Key Takeaway: Pacira BioSciences, Inc. is under legal scrutiny as Kahn Swick & Foti, LLC announced a class action lawsuit for investors who incurred losses exceeding $100,000 between August 2, 2023, and August 8, 2024. The lawsuit, pending in the U.S. District Court for New Jersey, claims that the company and some executives failed to disclose important information, violating federal securities laws. Following a patent infringement ruling against its Exparel product, which constitutes 80% of its revenue, shares plummeted by more than 47%, raising serious concerns for shareholders.

Market Sentiment Analysis

CONCERNS & RISKS

  • The company is facing a class action lawsuit due to alleged failure to disclose material information.
  • A recent lawsuit resulted in a significant drop in the company's share price by over 47%.

Full Press Release Details

NEW ORLEANS, March 04, 2025 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until March 14, 2025 to file lead plaintiff applications in a securities class action lawsuit against Pacira BioSciences, Inc. (the “Company”) (NasdaqGS: PCRX), if they purchased the Company’s securities between August 2, 2023 and August 8, 2024, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of New Jersey.
If you purchased securities of Pacira and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email (lewis.kahn@ksfcounsel.com), or visit https://www.ksfcounsel.com/cases/nasdaqgs-pcrx/ to learn more. If you wish to serve as a lead plaintiff in this class action, you must petition the Court by March 14, 2025.
Pacira and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On August 9, 2024, the Company released the results of its lawsuit against eVenus for patent infringement relating to its Exparel product, which accounts for approximately 80% of the Company’s revenue, disclosing that the U.S. District Court for the District of New Jersey had “found that the company’s U.S. Patent No. 11,033,495 is not valid,” and, thus, eVenus was not infringing on anything.
On this news, the price of Pacira’s shares fell over 47%, from a closing price of $22.36 per share on August 8, 2024 to a low of $11.70 per share on August 9, 2024.
The case is Alvarez v. Pacira BioSciences, Inc., et al., No. 25-cv-00322.
About Kahn Swick & Foti, LLC
KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms. KSF serves a variety of clients – including public institutional investors, hedge funds, money managers and retail investors – in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago and New Jersey.
To learn more about KSF, you may visit www.ksfcounsel.com.
Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
1100 Poydras St., Suite 960
New Orleans, LA 70163

Tags

Frequently Asked Questions

What is the deadline to file lead plaintiff applications?

The deadline to file lead plaintiff applications is March 14, 2025.

What period does the class action cover for Pacira securities?

The class action covers securities purchased between August 2, 2023, and August 8, 2024.

Why did Pacira's stock price drop significantly?

Pacira's shares fell over 47% after the court found its patent invalid, affecting revenue.

What is the case name associated with this action?

The case is named Alvarez v. Pacira BioSciences, Inc., et al., No. 25-cv-00322.

How can investors contact KSF for more information?

Investors can contact KSF's Lewis Kahn at 1-877-515-1850 or lewis.kahn@ksfcounsel.com.

Last updated: Mar 5, 2025